Vice President, Regulatory Affairs
Shirley Clift has served as Vice President, Regulatory Affairs since joining Sangamo in January 2010. Ms. Clift has over twenty years of biotechnology management experience in global regulatory affairs and cell and gene therapy product development. Throughout her career, she has been responsible for multiple corporate sponsored regulatory filings in the U.S., Europe, Japan, and Australia. Prior to joining Sangamo, Ms. Clift held various positions at Cell Genesys, Inc., including Vice President, Regulatory Affairs. Prior to joining Cell Genesys, Inc. in 1997, she held a variety of positions at Somatix Therapy Corp. Earlier in her career, she held various basic research positions at Lawrence Berkeley Laboratory, Genentech, Baylor College of Medicine, University of California, San Francisco, and Universidad Nacional Autonoma De Mexico. Ms. Clift received her B.A. degree from the University of California, Berkeley.
Edward Conner, M.D.
Senior Vice President and CMO
Edward Conner, M.D. has served as Senior Vice President and Chief Medical Officer since November 2016. He has over 10 years of industry experience in early and late stage clinical development in a broad range of disease areas including rare diseases, oncology and infectious diseases. Prior to joining Sangamo, Dr. Conner served as Vice President, Clinical Sciences at Ultragenyx Pharmaceuticals, a biopharmaceutical company developing novel products for the treatment of rare and ultra-rare diseases. Prior to joining Ultragenyx, he served as Senior Medical Director at BioMarin Pharmaceuticals Inc., where he led protocol development and regulatory interaction for its global phase 3 program in Pompe disease. From 2008 to 2013, Dr. Conner served as Medical Director at Genentech and was the clinical science team leader of two product candidates, including Xolair®, which is now a commercial drug product. He completed his Internal Medicine residency training at the University of Michigan and was a fellow in Clinical Immunology & Allergic Diseases at Johns Hopkins School of Medicine. He received a B.S. in Biology, cum laude, from Duke University and his M.D. from the University of California, San Francisco.
Nathalie Dubois-Stringfellow, Ph.D.
Vice President, Product Development and Management
Nathalie Dubois-Stringfellow, Ph.D., has served as Vice President, Product Development and Management since January 2015 and oversees the development and execution of project team strategy for Sangamo’s ZFP therapeutic programs in hemophilia, lysosomal storage disorders, hemoglobinopathies, HIV and Huntington’s disease. She has over 20 years of experience implementing and managing preclinical and clinical development of biologic therapies in oncology, as well as immune, infectious and genetic diseases. Dr. Dubois-Stringfellow joined Sangamo in January 2011 as Senior Director, Project Management. Prior to joining Sangamo, she held various positions in Discovery Research, Preclinical Research, Project Management, Clinical Development, and Portfolio Management at Chiron Corp., Bayer Corp., Signature Biosciences, Inc. and most recently XOMA LLC, where she served as Senior Director, Preclinical Portfolio and Alliance Management. Dr. Dubois-Stringfellow was a post-doctoral fellow at the University of North Carolina, Chapel Hill, where she studied angiogenesis and tumorigenesis in transgenic mice and cell culture systems. She received her M.S. in Genetics and Immunology, and her Ph.D. in Human Genetics from the Université Pierre et Marie Curie in Paris, France.
Chief of Staff
Heather Erickson has served as Chief of Staff since July 2016 and is responsible for the execution of Sangamo's daily operations and special projects. Prior to joining Sangamo, Ms. Erickson served as the President and CEO of the Life Sciences Foundation, a national research and education foundation focused on collecting and organizing the story of biotechnology and providing audiences with context for the role the life sciences play in society. From 2004 to 2012, Ms. Erickson founded and served as President of the MedTech Association, leading the industry trade organization to become the hub of Upstate New York’s bioscience and medical technology industry, with nearly 100 member companies and universities across the state, including Fortune 500 corporations. Prior to founding MedTech, she served as Senior Consultant at the San Francisco headquarters of Edgar, Dunn & Company, an international management consultancy specializing in strategic planning for the financial services industry. Ms. Erickson received a B.S. in Molecular, Cellular and Developmental Biology from Yale University.
Senior Vice President and CBO
Curt Herberts has served as Senior Vice President and Chief Business Officer since December 2016 and oversees Sangamo’s business functions and plans for commercialization of its therapeutics. Mr. Herberts has over 10 years of experience in commercial strategy and corporate development. He joined Sangamo in October 2010 as Director, Corporate Development & Strategy and was promoted to Senior Director in January 2012, and Vice President and Head of Corporate Development in July 2015. During this time, Sangamo established a number of collaborative agreements, including global collaborations with Shire plc, in 2012, and Biogen, Inc., in 2014. Prior to joining Sangamo, Mr. Herberts held several positions of increasing responsibility at Campbell Alliance Group, Inc., including leadership roles in the corporate development and commercial strategy practice areas. Prior to Campbell Alliance, he worked in business development, new product planning and technology transfer. Mr. Herberts holds an A.B. in Human Biology from Stanford University and a M.B.S. from Keck Graduate Institute School of Applied Life Sciences.
Michael Holmes, Ph.D.
Vice President, Research
Michael Holmes, Ph.D., has served as Vice President, Research since July 2015 and currently oversees Sangamo’s research activities. He joined Sangamo in May 2001 as a Scientist and became a Team Leader in 2002, focusing on the development of novel cell-based approaches to screen compound libraries. He was promoted to Director, Therapeutic Gene Modification in 2004, and Senior Director in 2009, where he pioneered the use of ZFNs for genome editing in transformed and primary human cells, including hematopoietic stem cells. Dr. Holmes has authored over 55 publications in the field of genome editing and gene regulation, as well as numerous patents. Prior to joining Sangamo, he worked as a post-doctoral fellow in Dr. Gerald Rubin’s lab at the University of California, Berkeley. Dr. Holmes received a B.S. in Molecular Biology from the University of California, San Diego, and his Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.
Sandy Macrae, M.B., Ch.B., Ph.D.
President and CEO
Sandy Macrae, M.B., Ch.B., Ph.D., has served as Sangamo’s President and Chief Executive Officer and as a member of the Board of Directors since June 2016. He has twenty years of experience in the pharmaceutical industry most recently serving as the Global Medical Officer of Takeda Pharmaceuticals, from 2012 to March 2016, where he established and led the Global Medical Office, which encompasses medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences and knowledge and informatics. From 2001 to 2012, Dr. Macrae held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President, Emerging Markets Research and Development (R&D), from 2009 to 2012. In that position, he provided expertise and resources to create a first-of-its-kind group to expand GSK’s global reach by providing R&D strategies, clinical development and regulatory resources to enter emerging markets and Asia-Pacific. From 2007 to 2008, he was Vice President, Business Development. In that position, he was responsible for scientific assessment and business development project leadership for the neurology, psychiatry, cardiovascular and metabolic therapeutic areas. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology. Dr. Macrae received his B.Sc. in pharmacology and his M.B., Ch.B. with honors from Glasgow University. He is a member of the Royal College of Physicians. Dr. Macrae also earned his Ph.D. in molecular genomics at King’s College, Cambridge.
Vice President, Human Resources
Leslie Mesones has served as Vice President, Human Resources since January 2017 and joined Sangamo in April 2015 as a Senior Director. Ms. Mesones has over 15 years of biopharmaceutical industry experience in human resource management, talent acquisition and recruiting. From 2013-2015, she served as Director, Human Resources at Mizuho OSI, a private medical device company with over 300 employees. Prior to that she served as Director, Human Resources at Zosano Pharma, a private pharmaceutical company focused on the delivery of CNS therapeutics. Earlier in her career Ms. Mesones held positions as Senior Manager, Human Resources at Theravance BioPharma US, Inc., as a Talent Acquisition Manager at Bayer Biological Products, a Bayer manufacturing site with 1300 employees, and as the Recruiting Manager at Axys Pharmaceuticals. Ms. Mesones received a B.A. in Spanish Literature from the University of California, Davis, and received her Career & Organizational Coaching Certificate from John F. Kennedy University.
Kathleen Meyer, M.P.H., Ph.D., D.A.B.T.
Vice President, Pharmacology, Toxicology and Bioanalytical Sciences
Kathleen Meyer, M.P.H., Ph.D., D.A.B.T., has served as Vice President, Pharmacology, Toxicology and Bioanalytical Sciences since January 2017, supporting the nonclinical development of Sangamo’s zinc finger protein-based genome editing and AAV-based gene therapy candidates. Dr. Meyer joined Sangamo as a Senior Director in 2014 with 20 years of industry experience in toxicology, bioanalytical development, pharmacokinetics, and nonclinical safety evaluation strategy and implementation of various biopharmaceuticals, including monoclonal antibody, enzyme replacement and gene therapies. Prior to joining Sangamo, Dr. Meyer served as Principal Scientist, Pharmacology and Toxicology at BioMarin Pharmaceutical Inc. where she guided small molecule and biologic drug candidates through the nonclinical development process, supporting clinical trials and marketing authorization. From 2009 to 2012, she served as Senior Director, Nonclinical Safety Evaluation at XOMA LLC and, prior to that, held positions as a Scientist and Principal Scientist at Elan Pharmaceuticals from 1997-2003. Before joining industry, she worked as a post-doctoral fellow evaluating non-viral methods of gene delivery in Dr. Frank Szoka Jr.’s laboratory at the University of California, San Francisco. Dr. Meyer received an A.B. in Physiology, a M.P.H. specializing in Toxicology and Epidemiology, and her Ph.D. in Environmental Health Science/Toxicology from the University of California, Berkeley. Dr. Meyer is a Diplomat of the American Board of Toxicology.
R. Andrew Ramelmeier, Ph.D.
Senior Vice President, Technical Operations
Edward Rebar, Ph.D.
Vice President, Technology
Edward Rebar, Ph.D., has served as Vice President, Technology since 2008, a capacity in which he directs the lead design and optimization for our therapeutic programs. Since joining Sangamo in 1998, Dr. Rebar has held several leadership positions at the company, including Senior Director, Technology, in which he led the development of Sangamo’s zinc finger protein design platform and co-managed the Company’s partnership with Sigma Aldrich. Dr. Rebar has authored over 55 publications relating to the development of customized DNA binding proteins and nucleases for genome editing, as well as numerous patents. Prior to joining Sangamo, he was a post-doctoral fellow at the University of California, Berkeley. Dr. Rebar earned his B.S. in Biochemistry from Rutgers University and his Ph.D. in Biophysics and Structural Biology from MIT.
Vice President, Corporate Communications and Investor Relations
McDavid Stilwell has served as Vice President, Corporate Communications and Investor Relations since November 2016. He has over 20 years of relevant experience across various business functions, including communications, investor relations, business development and financial analysis. Prior to joining Sangamo, Mr. Stilwell served as Vice President, Corporate Communications, Investor Relations & Business Development at Orexigen Therapeutics, Inc. From 2005 to 2012 he served as Director, Business Development, Corporate Communications and Financial Analysis at GTx, Inc., a development stage biopharmaceutical company. Earlier, Mr. Stilwell worked for five years as a Senior Investment Analyst for Shadwell Capital LLC, a hedge fund. Mr. Stilwell began his career as a journalist, first as a newspaper reporter and later as an executive editor of an investor newsletter covering financial services industry mergers and acquisitions. Mr. Stilwell received a B.A. in Liberal Arts from St. John’s College, Annapolis, Maryland, and a M.B.A. from Harvard Business School.
Senior Vice President and CFO
Kathy Yi has served as Senior Vice President and Chief Financial Officer since March 2017. Ms. Yi was formerly with Novartis Pharmaceuticals where she served as Head of Finance, Inhalation Technical Research & Development, responsible for the financial management of technical R&D organizations in California and Switzerland. Prior to joining Novartis, she was with Life Technologies Corp. from 2007 to 2014, during which time she held financial management positions of increasing seniority, including Finance Leader, Corporate FP&A. Prior to joining Life Technologies, Ms. Yi held various positions in finance at Intel Corp., from 2001 to 2007. She began her career as a Process/Project Engineer at Bechtel Corp., a leading global engineering, construction and project management company. Ms. Yi received a B.S. degree in Chemical Engineering from the University of California at Berkeley and an M.B.A. degree from Columbia Business School.